Company Cyfuse Biomedical K.K.

Equities

4892

JP3311800001

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-27 am EDT			5-day change	1st Jan Change
757 ^JPY	+2.57%		+1.75%	-0.66%

2023	Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	CI
2023	Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 28-FEB-2023.	CI

Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

Number of employees: 21

JPY in Million	2022	Weight	2023	Weight	Delta
Regenerative Medicine 70.2 %	120	32.0 %	43	70.2 %	-64.22%
Device 29.1 %	235	62.6 %	18	29.1 %	-92.42%
Drug Discovery Support 0.7 %	20	5.3 %	0	0.7 %	-97.88%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 98.6 %	332	88.7 %	60	98.6 %	-81.85%
United States 1.4 %	2	0.5 %	1	1.4 %	-55.92%

Managers	Title	Age	Since
Shizuka Akieda CEO	Chief Executive Officer	-	-
Masahiro Sanjo DFI	Director of Finance/CFO	-	-
Norihiko Tokunaga BRD	Director/Board Member	-	14-12-31

Members of the board	Title	Age	Since
Takuo Hirose BRD	Director/Board Member	52	-
Kunihiko Suzuki BRD	Director/Board Member	65	-
Shizuka Akieda CEO	Chief Executive Officer	-	-
Masahiro Sanjo DFI	Director of Finance/CFO	-	-
Yasuhiro Yoshioka BRD	Director/Board Member	-	-
Yoichi oda BRD	Director/Board Member	-	-
Kazuya Oda BRD	Director/Board Member	-	-
Norihiko Tokunaga BRD	Director/Board Member	-	14-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	8,130,800	5,171,900 ( 63.61 %)	0	63.61 %

Name	Equities	%	Valuation
SBI HOLDINGS, INC. 9.030 %	713,500	9.030 %	3 M ¥
SEKISUI CHEMICAL CO., LTD. 4.303 %	340,000	4.303 %	2 M ¥
Shizuka Akieda 4.255 %	336,200	4.255 %	2 M ¥
TAIYO HOLDINGS CO., LTD. 3.797 %	300,000	3.797 %	1 M ¥
CYBERDYNE INC. 2.953 %	233,300	2.953 %	1 M ¥
Masahiro Sanjo 2.935 %	231,900	2.935 %	1 M ¥
JAPAN TOBACCO, INC. 2.816 %	222,500	2.816 %	998 222 ¥
Nippon Venture Capital Corp. 2.810 %	222,000	2.810 %	995 979 ¥
MITSUBISHI HC CAPITAL INC. 2.531 %	200,000	2.531 %	897 278 ¥
PHC HOLDINGS CORPORATION 2.343 %	185,100	2.343 %	830 431 ¥

Cyfuse Biomedical KK

West Wing-1F 3-5-27

108-6301, Minato-ku

http://www.cyfusebio.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CYFUSE BIOMEDICAL K.K.	-0.66%	37.12M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+44.81%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research